All In Biotech

Drug Trial Radar · NCT06235242

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Feb 2, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).

Conditions

  • Adult
  • Non-small Cell Lung Cancer

Interventions

  • GT201 injection in combination with teraplizumab injectionBiological

    GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Profile Measured by Grade ≥3 TRAEsTime frame: 3 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Gobroad Hospital

    Beijing, Beijing Municipality, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai GoBroad Cancer Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.